Helyx Industries S.p.A. (BIT:HLX)

Italy · Delayed Price · Currency is EUR

0.7760

+0.0140 (1.84%)

Sep 25, 2026, 4:30 PM CET

Market Cap	20.21M -26.6%
Revenue (ttm)	1.93M +151.6%
Net Income	-4.38M
EPS	-0.17
Shares Out	26.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	0.7760
Previous Close	0.7620
Day's Range	0.7760 - 0.7760
52-Week Range	0.5600 - 1.4000
Beta	0.75
Analysts	Strong Buy
Price Target	1.17 (+50.77%)
Est. Earnings	Sep 28, 2026

About Helyx Industries

Helyx Industries S.p.A., a healthcare biotech company, develops, produces, and markets invitro diagnostic medical devices in Italy. The company through its Sagitta, a proprietary reagent platform designed to support deep multiplexing qPCR; and stable multiplex reagents. It also offers HYRIS bAPP, a software interface for managing and instructing Hyris system operations, as well as HYRIS bCUBE, an IVDR device compliant, designed according to industrial quality and operational safety criteria; and HYRIS bGATE, a gateway device that allows laborat... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 22

Stock Exchange Borsa Italiana

Ticker Symbol HLX

Full Company Profile

Financial Performance

In 2025, Helyx Industries's revenue was 1.93 million, an increase of 151.61% compared to the previous year's 767,929. Losses were -4.38 million, -26.32% less than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for HLX stock is "Strong Buy." The 12-month stock price target is €1.17, which is an increase of 50.77% from the latest price.

Price Target

€1.17

(50.77% upside)

Analyst Consensus: Strong Buy

Stock Forecasts